BR112015004119A2 - anticorpos monoclonais para melhorar ou inibir o fator de crescimento semelhante à insulina tipo 1 (igf-1) - Google Patents
anticorpos monoclonais para melhorar ou inibir o fator de crescimento semelhante à insulina tipo 1 (igf-1)Info
- Publication number
- BR112015004119A2 BR112015004119A2 BR112015004119A BR112015004119A BR112015004119A2 BR 112015004119 A2 BR112015004119 A2 BR 112015004119A2 BR 112015004119 A BR112015004119 A BR 112015004119A BR 112015004119 A BR112015004119 A BR 112015004119A BR 112015004119 A2 BR112015004119 A2 BR 112015004119A2
- Authority
- BR
- Brazil
- Prior art keywords
- igf
- insulin
- improve
- growth factor
- monoclonal antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
abstract the present invention provides an antibody or antigen-binding fragment thereof that binds avß3 integrin, as well as methods of use in the treatment of diseases and disorders. tradução do resumo resumo patente de invenção: "anticorpos monoclonais para melhorar ou inibir o fator de crescimento semelhante à insulina tipo 1 (igf-1)". a presente invenção refere-se a um anticorpo ou fragmento de ligação ao antígeno que se liga à integrina a?ß3, bem como métodos de utilização no tratamento de doenças e distúrbios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261695409P | 2012-08-31 | 2012-08-31 | |
PCT/US2013/057484 WO2014036385A1 (en) | 2012-08-31 | 2013-08-30 | Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015004119A2 true BR112015004119A2 (pt) | 2017-08-08 |
Family
ID=50184409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015004119A BR112015004119A2 (pt) | 2012-08-31 | 2013-08-30 | anticorpos monoclonais para melhorar ou inibir o fator de crescimento semelhante à insulina tipo 1 (igf-1) |
Country Status (13)
Country | Link |
---|---|
US (3) | US9073996B2 (pt) |
EP (1) | EP2890716A4 (pt) |
JP (1) | JP2015533117A (pt) |
KR (1) | KR20150047602A (pt) |
CN (1) | CN104768975A (pt) |
AU (1) | AU2013308568A1 (pt) |
BR (1) | BR112015004119A2 (pt) |
CA (1) | CA2882757A1 (pt) |
HK (1) | HK1213904A1 (pt) |
IL (1) | IL237279A0 (pt) |
MX (1) | MX2015002465A (pt) |
RU (1) | RU2015106333A (pt) |
WO (1) | WO2014036385A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8187595B2 (en) | 2004-05-07 | 2012-05-29 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I |
ES2457822T3 (es) * | 2007-11-08 | 2014-04-29 | The General Hospital Corporation | Procedimientos y composiciones de tratamiento de enfermedades proteinúricas |
EP2812443B1 (en) | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
RU2015106333A (ru) | 2012-08-31 | 2016-10-27 | Зэ Юниверсити Оф Норз Каролина Эт Чапел Хилл | Моноклональные антитела для стимуляции или ингибирования инсулиноподобного фактора роста 1 (igf-1) |
SG11201508911PA (en) | 2013-04-29 | 2015-11-27 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
JP6778110B2 (ja) | 2014-01-15 | 2020-10-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 改善されたプロテインA結合を有するFc領域バリアント |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1297815C (en) | 1985-06-07 | 1992-03-24 | Barry S. Coller | Fibrinogen blocking monoclonal antibody |
ES2095959T3 (es) | 1990-10-24 | 1997-03-01 | Allelix Biopharma | Inhibidores de la replicacion del virus vih a base de peptidos. |
WO1993020229A1 (en) | 1992-04-03 | 1993-10-14 | Genentech, Inc. | ANTIBODIES TO ALPHAvBETA3 INTEGRIN |
GB9317423D0 (en) * | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
MXPA01005562A (es) * | 1998-11-03 | 2003-08-01 | Centocor Inc | Anticuerpos y fragmentos de anticuerpos modificados con mayor duracion de actividad. |
WO2000055181A1 (en) | 1999-03-15 | 2000-09-21 | The General Hospital Corporation | Methods of modulating cell attachment and migration |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
US8187595B2 (en) | 2004-05-07 | 2012-05-29 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I |
DK1755660T3 (da) | 2004-05-07 | 2010-07-19 | Univ North Carolina | Fremgangsmåde til forbedring eller hæmning af insulin-lignende vækstfaktor-I |
US8093360B2 (en) * | 2006-09-28 | 2012-01-10 | Elusys Therapeutics, Inc. | Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use |
US8323654B2 (en) * | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
EP2025685B1 (en) * | 2007-08-15 | 2013-06-19 | Canadian Blood Services | Monoclonal antibodies against BETA3 integrins |
ES2457822T3 (es) | 2007-11-08 | 2014-04-29 | The General Hospital Corporation | Procedimientos y composiciones de tratamiento de enfermedades proteinúricas |
WO2010054189A1 (en) | 2008-11-06 | 2010-05-14 | University Of Miami | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
RU2015106333A (ru) | 2012-08-31 | 2016-10-27 | Зэ Юниверсити Оф Норз Каролина Эт Чапел Хилл | Моноклональные антитела для стимуляции или ингибирования инсулиноподобного фактора роста 1 (igf-1) |
-
2013
- 2013-08-30 RU RU2015106333A patent/RU2015106333A/ru not_active Application Discontinuation
- 2013-08-30 MX MX2015002465A patent/MX2015002465A/es unknown
- 2013-08-30 AU AU2013308568A patent/AU2013308568A1/en not_active Abandoned
- 2013-08-30 WO PCT/US2013/057484 patent/WO2014036385A1/en active Application Filing
- 2013-08-30 US US14/015,457 patent/US9073996B2/en not_active Expired - Fee Related
- 2013-08-30 BR BR112015004119A patent/BR112015004119A2/pt not_active IP Right Cessation
- 2013-08-30 EP EP13832446.2A patent/EP2890716A4/en not_active Withdrawn
- 2013-08-30 JP JP2015530087A patent/JP2015533117A/ja active Pending
- 2013-08-30 KR KR1020157007804A patent/KR20150047602A/ko not_active Application Discontinuation
- 2013-08-30 CA CA2882757A patent/CA2882757A1/en not_active Abandoned
- 2013-08-30 CN CN201380056200.2A patent/CN104768975A/zh active Pending
-
2015
- 2015-02-17 IL IL237279A patent/IL237279A0/en unknown
- 2015-06-02 US US14/728,379 patent/US9587024B2/en active Active
-
2016
- 2016-01-04 HK HK16100022.4A patent/HK1213904A1/zh unknown
-
2017
- 2017-02-22 US US15/439,654 patent/US20180016340A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2890716A4 (en) | 2016-06-08 |
US20150259422A1 (en) | 2015-09-17 |
HK1213904A1 (zh) | 2016-07-15 |
CN104768975A (zh) | 2015-07-08 |
CA2882757A1 (en) | 2014-03-06 |
US20180016340A1 (en) | 2018-01-18 |
IL237279A0 (en) | 2015-04-30 |
EP2890716A1 (en) | 2015-07-08 |
RU2015106333A (ru) | 2016-10-27 |
AU2013308568A1 (en) | 2015-04-09 |
WO2014036385A1 (en) | 2014-03-06 |
US9587024B2 (en) | 2017-03-07 |
MX2015002465A (es) | 2015-11-06 |
KR20150047602A (ko) | 2015-05-04 |
JP2015533117A (ja) | 2015-11-19 |
US9073996B2 (en) | 2015-07-07 |
US20140072568A1 (en) | 2014-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
BR112015004119A2 (pt) | anticorpos monoclonais para melhorar ou inibir o fator de crescimento semelhante à insulina tipo 1 (igf-1) | |
UA114891C2 (uk) | ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ | |
UY33407A (es) | Anticuerpos específicos del factor gdf8 humano | |
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
AR092818A1 (es) | Anticuerpo tau humanizado | |
AU2018256498A1 (en) | Antibodies to amyloid beta | |
EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
CL2015001314A1 (es) | Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14). | |
NZ630363A (en) | Anti-kit antibodies and uses thereof | |
CR20140029A (es) | Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada | |
BR112014009962A2 (pt) | anticorpos humanizados para inkt | |
BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
BR112013004056B8 (pt) | Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende | |
BR112013020500A2 (pt) | anticorpo isolado, recombinante ou purificado | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
BR112015012708A2 (pt) | anticorpos para bmp-6 | |
BR112014027991A2 (pt) | agentes para neutralização de influenza | |
CO6602134A2 (es) | Proteinas de union a antigeno especificas para componente amiloide serico p | |
UA117657C2 (uk) | Антитіло до трансглютамінази 2 (tg2) | |
BR112018015090A2 (pt) | anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |